Standardization of two immunoassays for human glandular kallikrein 2

Clinical Chemistry

Volumn 49, Issue 4, 2003, Pages 601-610

  Haese, Alexander ^a,e   Vaisanen, Ville ^c   Finlay, Judith A ^b   Pettersson, Kim ^c   Rittenhouse, Harry G ^b   Partin, Alan W ^a   Bruzek, Debra J ^a   Sokoll, Lori J ^a   Lilja, Hans ^d   Chan, Daniel W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Hybritech Incorporated   (United States)

^c UNIVERSITY OF TURKU   (Finland)

^d LUND UNIVERSITY   (Sweden)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE KALLIKREIN; TISSUE KALLIKREIN 2; UNCLASSIFIED DRUG;

AMINO ACID ANALYSIS; ARTICLE; CALIBRATOR; CONTROLLED STUDY; DILUTION; EARLY DIAGNOSIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PROSTATE CANCER; PROTEIN DETERMINATION; STANDARDIZATION;

CALIBRATION; FLUOROMETRY; HUMANS; IMMUNOASSAY; MALE; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; REFERENCE STANDARDS; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037379953     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.4.601     Document Type: Article

References (34)

1. Chapdelaine P, Paradis G, Tremblay RR, Dube JY. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 1988;236:205-8.
2. Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of a human glandular kallikrein gene. DNA 1987;6:429-37.
3. 2+ and extracellular protease inhibitors. Eur J Biochem 1999;262:781-9.
4. Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997;238:549-55.
5. Young CY, Andrews PE, Montgomery BT, Tindall DJ. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 1992;31:818-24.
6. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 1997;49:857-62.
7. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999;53:939-44.
8. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-6.
9. 1-antichymotrypsin. Clin Chem 1991;37:1618-25.
10. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100-5.
11. Deperthes D, Chapdelaine P, Tremblay RR, Brunet C, Berton J, Hebert J, et al. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim Biophys Acta 1995;1245:311-6.
12. Grauer LS, Finlay JA, Mikolajczyk SD, Pusateri KD, Wolfert RL. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate cancer serum. J Androl 1998;19:407-11.
13. Piironen T, Lovgren J, Karp M, Eerola R, Lundwall A, Dowell B, et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996;42:1034-41.
14. Finlay JA, Evans CL, Day JR, Payne JK, Mikolajczyk SD, Millar LS, et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998;51:804-9.
15. Finlay JA, Day JR, Evans CL, Carlson R, Kuus-Reichel K, Millar LS, et al. Development of a dual monoclonal antibody immunoassay for total human kallikrein 2. Clin Chem 2001;47:1218-24.
16. Becker C, Piironen T, Kiviniemi J, Lilja H, Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 2000;46:198-206.
17. Black M, Magklara A, Obiezu C, Melegos DN, Diamandis EP. Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem 1999;45:790-9.
18. Saedi MS, Hill TM, Kuus-Reichel K, Kumar A, Payne J, Mikolajczyk SD, et al. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 1998;44:2115-9.
19. Klee GG, Goodmanson MK, Jacobsen SJ, Young CY, Finlay JA, Rittenhouse HG, et al. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 1999;45:800-6.
20. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 2000;18:1036-42.
21. Becker C, Piironen T, Pettersson K, Bjork T, Wojno KJ, Oesterling JE, et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 2000;163:311-6.
22. Partin AW, Catalona WJ, Finlay JA, Darte C, Tindall DJ, Young CY, et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 1999;54:839-45.
23. Kwiatkowski M, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 1998;52:360-5.
24. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines DR. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 2000;46:1310-7.
25. Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Huber A, Lummen G, et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 2000;55:481-5.
26. Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H, et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol 2000;163:1491-7.
27. Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49:101-9.
28. Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology 2000;55:694-9.
29. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 1998;34:44-50.
30. Lovgren J, Tian S, Lundwall A, Karp M, Lilja H. Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. Eur J Biochem 1999;266:1050-5.
31. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, et al. A precursor form of PSA (pPSA) is a component of free PSA in prostate cancer serum. Urology 1997;50:710-4.
32. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61:6958-63.
33. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free PSA in serum is becoming more complex. Urology 2002;59:797-802.
34. 146 inactive PSA. Clin Chem 2000;46:1610-8.